- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | Conexeu Sciences schließt Privatplatzierung über 4 Millionen US-Dollar ab und gibt nicht registrierte Aktien aus | - | Investing.com Deutsch | ||
| 20.10. | Conexeu Sciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.10. | Conexeu Sciences closes $5 million private placement | 2 | Investing.com | ||
| 15.10. | Conexeu Sciences Inc.: Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors | 1 | GlobeNewswire (USA) | ||
| 06.10. | Conexeu Sciences Inc.: Conexeu Sciences Advances Ten Minute Tissue Toward Planned FDA 510(k) Submission | 1 | GlobeNewswire (USA) | ||
| 10.09. | Conexeu Sciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Conexeu Sciences Inc.: Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration | 3 | GlobeNewswire (USA) | ||
| CONEXEU SCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.07. | Conexeu Sciences Inc.: The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It | 1 | GlobeNewswire (USA) | ||
| 09.07. | One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics | 4 | CNW | ||
| 07.07. | Conexeu Sciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.07. | Conexeu Sciences Inc.: A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill | 1 | GlobeNewswire (USA) | ||
| 25.06. | Conexeu Sciences Inc.: Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform | 1 | GlobeNewswire (USA) | ||
| 22.06. | Conexeu Sciences stock initiated at buy by H.C. Wainwright, $20 target | 1 | Investing.com | ||
| 15.06. | Conexeu Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.06. | Conexeu Sciences Inc.: Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing | 328 | GlobeNewswire (Europe) | RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, today announced additions to... ► Artikel lesen | |
| 09.06. | Conexeu Sciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Conexeu Sciences: Aktie legt nach Fortschritten bei Wundversorgungs-Produkt zu | 1 | Investing.com Deutsch | ||
| 08.06. | Conexeu forciert Produktionsaufbau für Wundpflege-Produkt vor geplantem FDA-Antrag 2027 | - | Investing.com Deutsch | ||
| 08.06. | Conexeu Sciences Inc.: Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU Wound Care Program | 1 | GlobeNewswire (USA) | ||
| 03.06. | Conexeu Sciences Inc.: Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026 | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,706 | -0,13 % | Piper Sandler raises Teladoc stock price target on BetterHelp growth | ||
| SERNOVA BIOTHERAPEUTICS | 0,068 | +21,15 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 1,420 | -2,61 % | Cerenome completes enrollment in glioblastoma drug trial | ||
| ATOSSA THERAPEUTICS | 2,040 | +0,99 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 17,000 | +1,80 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,353 | -0,03 % | Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India | CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile... ► Artikel lesen | |
| QUIDELORTHO | 11,630 | -7,18 % | Quidel Q3 2026 Earnings Preview | ||
| VERU | 2,160 | 0,00 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data | ||
| LIFEWARD | 6,040 | -1,31 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 3,840 | -0,52 % | Clover Health im Aufwind: Needham startet Coverage mit "Buy" und Kursziel von 6 Dollar | ||
| SENSEONICS | 8,000 | -0,62 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| NANO-X IMAGING | 0,302 | +0,03 % | NANO-X IMAGING LTD: TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI's AVC Solution | ||
| TEMPEST THERAPEUTICS | 0,472 | +0,06 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| IMUNON | 0,790 | 0,00 % | Imunon, Inc. - S-1, General form for registration of securities |
Das Unternehmen CONEXEU SCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,395 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CONEXEU SCIENCES INC finden Sie auf Wallstreet Online.